Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,714 total articles
Sagimet Biosciences announced plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. starting in the second half of 2026, following positive Phase 3 results reported in China. The company is also advancing its FASN inhibitor pipeline with an ongoing Phase 1 trial of TVB-3567 and is prioritizing dermatology…
Ocular Therapeutix, a biopharmaceutical company focused on retinal disease treatments, has announced its participation in various upcoming scientific and investor conferences in May 2026. The company will present clinical trial results, particularly for its investigational product AXPAXLI (OTX-TKI), currently in Phase 3 trials for wet age-related m…
Intellia Therapeutics has started a rolling submission of a biologics license application to the FDA seeking approval for lonvoguran ziclumeran (lonvo-z), an innovative one-time in vivo CRISPR gene-editing treatment for hereditary angioedema (HAE). Positive topline Phase 3 HAELO trial data indicate that lonvo-z met primary and secondary endpoints, …
Harrow, a Nasdaq-listed ophthalmic disease management company, will release its financial results for Q1 2026 after market close on May 11, followed by a conference call on May 12 to discuss the results and provide a business update.
Cardiff Oncology announced it will host a key opinion leader webinar on April 30, 2026, to discuss data from an investigator-initiated trial showing onvansertib's promising single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The event features Dr. Mrinal Patnaik from Mayo Clinic and aims to highlight onvansertib's potential as…
U.S. Energy Corp. (NASDAQ: USEG) announced a five-year helium sales agreement with an investment-grade global industrial gas company for helium produced at its Big Sky Carbon Hub in Montana. The contract guarantees purchase of 100% of Phase 1 helium production at a fixed plant-gate price of $285 per thousand cubic feet with annual inflation adjustm…
GXO Logistics, the largest pure-play contract logistics provider, announced its partnership with the Arrow McLaren IndyCar Team as an Official Partner for the 110th Running of the Indianapolis 500. GXO branding will be prominently featured on the No. 31 car driven by Ryan Hunter-Reay. This partnership aligns GXO's values of teamwork, precision, and…
Intellia Therapeutics reported positive topline results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene editing therapy targeting hereditary angioedema (HAE). The trial met its primary and all key secondary endpoints, showing an 87% reduction in attacks over six months versus placebo, with favo…
Altimmune, Inc. has completed an oversubscribed public offering raising $225 million in gross proceeds to fund its upcoming Phase 3 clinical trial of pemvidutide, a novel therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) and other serious liver diseases. The financing provides cash runway through the anticipated 52-week data…
Martin Marietta Materials, Inc., a leading supplier of aggregates and building materials, appointed Chris Samborski as Executive Vice President and Chief Operating Officer effective May 1, 2026. Samborski brings extensive leadership experience from his previous roles within Martin Marietta and other major corporations such as Caterpillar and Johnso…
Verizon Communications Inc. reported solid financial and operating results for the first quarter of 2026, showcasing accelerating momentum in its strategic transformation efforts. The company achieved its highest quarterly adjusted EBITDA in history, positive postpaid phone net additions for the first time in over a decade, and raised its 2026 adju…
Oruka Therapeutics announced positive interim data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis patients. The treatment achieved a 63.5% complete skin clearance rate (PASI 100) at 16 weeks with a safety profile similar to placebo and existing IL-23p19 inhibitors. Updated pharmacokinetic data support potentia…
Astec Industries, a manufacturer of specialized equipment for asphalt road building, aggregate processing, and concrete production, announced a quarterly dividend of $0.13 per share payable on May 29, 2026, to shareholders of record on May 13, 2026. The company operates in two main segments: Infrastructure Solutions and Materials Solutions, and als…
Sionna Therapeutics has completed enrollment in its PreciSION CF Phase 2a proof-of-concept trial, which evaluates its first-in-class NBD1 stabilizer, SION-719, added to the current cystic fibrosis standard of care Trikafta. Data from the trial is expected in summer 2026. This marks the first clinical study targeting the nucleotide binding domain 1 …
Fulcrum Therapeutics announced positive clinical data from its Phase 1b PIONEER trial of pociredir for sickle cell disease, showing significant fetal hemoglobin induction and improvements in markers of hemolysis, anemia, and potential reduction in vaso-occlusive crises. The company plans to initiate a registration-enabling trial in the second half …
Lakeland Financial Corporation announced record first quarter 2026 net income of $26.5 million, a 32% increase from the prior year quarter, driven by 5% loan growth, strong net interest margin expansion, and 18% higher noninterest income. The bank experienced healthy organic loan growth, improved asset quality, and increased shareholder returns via…
Aeluma, a NASDAQ-listed semiconductor company, has appointed Dr. Willy Rachmady as Vice President of Strategic Partnerships and Ecosystem. With over 20 years at Intel and extensive expertise in advanced semiconductor technologies, Dr. Rachmady will focus on building strategic manufacturing partnerships and accelerating commercialization of Aeluma's…
SCHMID Group N.V. announced preliminary Q1 2026 results with order intake of €13.6 million and revenues of €18.2 million, noting Q1 is traditionally soft. The company reaffirmed its full-year 2026 guidance expecting revenues over €100 million, an Adjusted EBITDA margin above 12%, and order intake around €114 million. Significant financial maneuvers…
Fulcrum Therapeutics appointed Dr. Josh Lehrer, a seasoned physician-scientist with extensive drug development experience in rare diseases, to its Board of Directors. Dr. Lehrer’s background includes leadership roles in developing therapies for sickle cell disease, notably contributing to the approval of Oxbryta. His addition is expected to bolster…
Eton Pharmaceuticals has begun dosing patients in a clinical pilot study for ET-700, an extended-release zinc acetate formulation targeting treatment of Wilson disease. The study aims to evaluate ET-700's efficacy in reducing intestinal copper absorption with a simpler dosing regimen. Positive results expected in late 2026 could lead to a pivotal t…
Amaze Holdings, Inc. (NYSE American: AMZE) announced an LOI to integrate Digital Innovations Holding Group's proprietary IRMA engine into its platform, aiming to create a new monetization layer for creators and fans via paid influencer programs. This integration will introduce the Amaze credit system to reward participation, promote affiliate commi…
Parsons Corporation, a leading national security and infrastructure technology company, has commenced work as lead designer on the State Route 400 Express Lanes Project in Georgia. This $4.6 billion initiative, the largest transportation public-private partnership in the U.S., aims to improve mobility, reduce congestion, and promote economic growth…
Super Hi International Holding Ltd., operator of internationally recognized Haidilao hot pot restaurants, announced its annual general meeting to be held virtually on June 12, 2026. The company has also filed its annual report on Form 20-F for the fiscal year ending December 31, 2025, reflecting its financial performance and operational status.
OwlTing Group, a Nasdaq-listed global fintech company, announced it will release its financial results for the full year ended December 31, 2025 after the U.S. market closes on April 29, 2026. The company will also hold a management conference call on April 30 to discuss these results and recent business developments. OwlTing is recognized as a hig…
EUDA Health Holdings Limited has received a notice from Nasdaq stating it failed to maintain the required minimum market value of listed securities ($35 million) for 32 consecutive business days. The company has 180 days to regain compliance or face potential delisting from the Nasdaq Capital Market.
